Keytruda plus radiation shows promise against lung cancer
NCT ID NCT02444741
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with precise radiation therapy could help people with advanced non-small cell lung cancer. The trial enrolled 124 participants with stage IV disease. The goal was to see if the combination could shrink tumors and slow cancer growth. The approach uses radiation to kill cancer cells while pembrolizumab helps the immune system attack the cancer throughout the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda) plus radiation therapy
What this could lead to
If successful, this combination could offer a new treatment option for advanced lung cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong
This is an early-phase trial (Phase I/II) with a modest number of participants. Results may not apply to all patients, and side effects from combining immunotherapy with radiation are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States